MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

917.65 -3.83 (-0.42%)
Official Closing Price Updated: 7:00 PM EDT, Apr 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗
The stock could have plenty of room to run from current levels. 
Via The Motley Fool
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
These companies boast significant upside potential. 
Via The Motley Fool
News headline image
Should You Forget CVS Health and Invest in a Purer Healthcare Play? ↗
There are other factors to consider before investing in this -- or any other -- healthcare company. 
Via The Motley Fool
News headline image
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson ↗
MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data. 
Via Benzinga
News headline image
Is This $6.3 Billion Deal a Game Changer for Eli Lilly? ↗
It's acquiring an asset with a very promising lead drug candidate. 
Via The Motley Fool
News headline image
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar ↗
Eli Lilly Foundayo shows cardiovascular safety and stronger A1C, weight reduction, while the FDA flags liver risk, seeks additional data. 
Via Benzinga
News headline image
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market ↗
Lilly's revenue has soared thanks to its obesity drugs. 
Via The Motley Fool
News headline image
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust ↗
And can Novo Nordisk catch up to its rival in the weight loss market? 
Via The Motley Fool
News headline image
Worried About a Stock Market Crash? These 3 Stocks Beat the S&P 500 by Wide Margins When It Nosedived in 2022, and They Could Do It Again ↗
During the last market crash, these stocks all generated positive returns -- one as high as 80%. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Revolution Medicines (RVMD): The New Titan of the RAS Pathway (2026 Research Feature)
As of April 15, 2026, the biotechnology sector is witnessing a paradigm shift in precision oncology, spearheaded by Revolution Medicines, Inc. (Nasdaq: RVMD). Once considered a high-risk clinical-stage... 
Via Finterra
Topics Initial Public Offering
News headline image
Could AbbVie Crash Lilly's Weight‑Loss Party? ↗
AbbVie is making progress in this market, but it is still far behind the leader. 
Via The Motley Fool
News headline image
Amazon (AMZN) Stock Is Up, What You Need To Know
What Happened? Shares of cloud computing and online retail behemoth Amazon (NASDAQ:AMZN) jumped 3.6% in the afternoon session after the company announced it ... 
Via StockStory
Topics Artificial Intelligence
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc.... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Via Get News
Topics Intellectual Property
News headline image
After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock? ↗
In April, regulators approved Foundayo, Eli Lilly's GLP-1 pill for weight loss. 
Via The Motley Fool
News headline image
The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)
As of April 13, 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) stands as a pivotal player in the rapidly evolving field of radiopharmaceuticals—a sector that has transformed from a niche... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Eli Lilly's Jaypirca Builds Case With Fourth Positive Phase 3 Trial In Blood Cancer Patients ↗
Eli Lilly releases positive Phase 3 data for Jaypirca and Retevmo, with trial results supporting potential label expansion. 
Via Benzinga
News headline image
Eli Lilly & Co (NYSE:LLY) Presents a Prime Case for Affordable Growth Investing ↗
Eli Lilly (LLY) exemplifies the GARP strategy with strong growth, reasonable valuation relative to peers, and robust profitability for sustainable returns. 
Via Chartmill
News headline image
3 Mid-Cap Stocks Walking a Fine Line
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
News headline image
1 Profitable Stock to Own for Decades and 2 That Underwhelm
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
The Post-Ozempic Economy? 2 Industries Bracing for a Slimmer, Less Hungry America ↗
The use of weight-loss drugs is growing like crazy and changing the entire consumer economy along with it. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire ↗
And it's not too late to get in on the action. 
Via The Motley Fool
News headline image
Here's Why Buying This Vanguard Index Fund Today Could Be the Best Financial Decision You Ever Make ↗
The Vanguard S&P 500 ETF is a no-brainer for investors seeking more diversification in their portfolio. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Earnings
News headline image
Amazon (AMZN) Stock Trades Up, Here Is Why
What Happened? Shares of cloud computing and online retail behemoth Amazon (NASDAQ:AMZN) jumped 4.5% in the afternoon session after CEO Andy Jassy's annual s... 
Via StockStory
Topics Artificial Intelligence
News headline image
The Global Pantry Reimagined: Unilever and McCormick Seal $65 Billion Merger Deal
In a move that has sent shockwaves through the global consumer staples market, Unilever (NYSE:UL) and McCormick & Company (NYSE:MKC) have officially entered into a definitive agreement to merge... 
Via MarketMinute
Topics Economy Supply Chain
News headline image
Eli Lilly Just Launched Its $149 Obesity Pill ↗
Eli Lilly launches Foundayo weight-loss pill after FDA approval, priced from $149/month, as competition with Novo Nordisk intensifies. 
Via Benzinga
News headline image
What to Expect From Eli Lilly's Next Quarterly Earnings Report
Eli Lilly is approaching its first-quarter earnings release this month, and Wall Street is forecasting a triple-digit percentage rise in earnings. 
Via Barchart.com
Topics ETFs
News headline image
What's Going On With GoodRx Stock Thursday? ↗
GoodRx shares rise after expanding Eli Lilly's GLP-1 access; analysts keep Buy rating ahead of May earnings. 
Via Benzinga
News headline image
Eli Lilly Faces Pressure In India As Cheaper GLP-1 Rivals Dent Mounjaro Sales ↗
Eli Lilly and Co. is facing mounting pressure in India as a surge rise in lower-cost generic alternatives dent sales. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story